Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.70
-0.1600-3.29%
Pre-market: 4.740.0400+0.85%06:34 EST
Volume:17.19M
Turnover:81.28M
Market Cap:2.44B
PE:-2.63
High:4.80
Open:4.80
Low:4.65
Close:4.86
52wk High:12.36
52wk Low:3.79
Shares:519.84M
Float Shares:415.00M
Volume Ratio:0.82
T/O Rate:4.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7839
EPS(LYR):-1.6909
ROE:-91.06%
ROA:-42.04%
PB:2.33
PE(LYR):-2.78

Loading ...

Recursion Pharmaceuticals Director Christopher Gibson Reports Sale of Common Shares

Reuters
·
Yesterday

Recursion Pharmaceuticals (RXRX): Assessing Valuation After New Activist Investor Filings With the SEC

Simply Wall St.
·
Jan 05

Getty Images, Torm, and More Stocks See Action From Activist Investors -- Barrons.com

Dow Jones
·
Jan 03

Recursion CFO Ben R. Taylor Reports Sale of Common Shares

Reuters
·
Dec 31, 2025

Chief R&D Commercial Officer Najat Khan Sells Recursion Pharmaceuticals Common Shares

Reuters
·
Dec 30, 2025

3 Small AI Plays to Buy for 2026

Benzinga_recent_news
·
Dec 27, 2025

Recursion Pharmaceuticals CEO Christopher Gibson Reports Sale of Common Shares

Reuters
·
Dec 20, 2025

Recursion Pharmaceuticals (RXRX): Valuation Check After Encouraging TUPELO Trial Data and Analyst Upgrades

Simply Wall St.
·
Dec 19, 2025

Nvidia-Linked Shares Shined. WhiteFiber Up 18%; CoreWeave Up 6%; Nebius And APLD Up 4%; Recursion, Core Scientific And Nano-X Up 3%

Tiger Newspress
·
Dec 19, 2025

Cathie Wood Dumps $11 Milllion Worth of Tesla Stock While Doubling Down on These Notable Crypto Plays

Benzinga
·
Dec 19, 2025

JPMorgan Upgrades Recursion Pharmaceuticals (RXRX.US) to "Overweight," Citing Blockbuster Potential for Core Asset REC-4881

Stock News
·
Dec 18, 2025

Cathie Wood's Big Crypto Bet: Ark Scoops up Bitmine, Coinbase and Bullish, Dumps This Amazon Rival

Benzinga
·
Dec 18, 2025

Recursion Pharmaceuticals Shares Rise After JPMorgan Upgrade

MT Newswires Live
·
Dec 18, 2025

Recursion Pharmaceuticals Rises 13.1% After JP Morgan Raises Co to 'Overweight' From 'Neutral'

THOMSON REUTERS
·
Dec 17, 2025

JPMorgan Upgrades Recursion Pharmaceuticals to Overweight From Neutral, Adjusts PT to $11 From $10

MT Newswires Live
·
Dec 17, 2025

Why Are Shares Of Recursion Pharmaceuticals Higher Today?

Benzinga_recent_news
·
Dec 08, 2025

Recursion Pharmaceuticals Shares up 6.1% After Co's Experimental Therapy Reduces Polyp Growth in Rare Disease Trial

THOMSON REUTERS
·
Dec 08, 2025

BUZZ-Recursion climbs as experimental drug reduces polyp growth in rare disease trial

Reuters
·
Dec 08, 2025

Recursion Reports Positive Phase 2 Results for REC-4881 in Familial Adenomatous Polyposis

Reuters
·
Dec 08, 2025

BRIEF-Recursion's Tupelo Trial Phase 1B/2 Results Show Polyp Burden Reductions In FAP At 25 Weeks

Reuters
·
Dec 08, 2025